RET and medullary thyroid gland carcinoma: Cabozantinib and vandetanib have been approved for first-line treatment in MTC regardless of RET mutational status, even if the presence of RET mutations, particularly the RET p.M918T mutation, seems to be associated with a better response to cabozantinib in terms of overall response rate and progression-free survival (62, 63).